November 06, 2009 13:59 ET

Ever-Tenacious Ossur to Ring NASDAQ Closing Bell

ALISO VIEJO, CA--(Marketwire - November 6, 2009) - On Monday, November 9, Jon Sigurdsson, president and CEO of Ossur Hf., will mark the company's tenth year of trading publically on NASDAQ OMX Iceland, and also commemorate its new dual listing on NASDAQ OMX Copenhagen, by ringing the NASDAQ stock market Closing Bell in New York City.

Ossur is the proud Icelandic developer and manufacturer of non-invasive orthopaedics that has survived a most challenging year. A global leader in its category, the company has weathered the storm thanks to its clear focus on improving people's mobility through the delivery of innovative technologies within the fields of bracing and supports, prosthetic limbs and compression therapies.

"Our outlook has always been on a global scale, and this thinking has served us well," said Mr. Sigurdsson, a World Economic Forum TechPioneer alumnus. "It is especially fitting that we should celebrate this honor in the United States, where we have extensive operations and have enjoyed an increase in sales in the 3rd Quarter of this year," he added. Ossur is best known as the purveyor of the Cheetah Flex-Foot, the prosthetic device of choice for elite amputee athletes like Oscar Pistorius who recently challenged the IAAF for the right to compete against able-bodied athletes in the Olympics, and won. It is also the first company in the world to bring bionic prosthetic feet and knees to market, including the RHEO KNEE, the POWER KNEE, and the PROPRIO FOOT. In the past five years, Ossur acquired a number of orthopaedic companies, and is renowned for its proven solution for Knee Osteoarthritis, the Unloader One brace.

About Ossur

Ossur (Nasdaq OMX: OSSR/ OSSR DKK) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports, prosthetic limbs and compression therapies. A recognized "Technology Pioneer," Ossur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Ossur's educational programs and business solutions. Headquartered in Iceland, Ossur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. Website:

Contact Information

  • Contacts:

    Ossur Investor Relations
    Sigurborg Arnarsdóttir
    Tel.: +354 515 1339
    Fax: +354 515 1366
    Email Contact

    Beverly Millson
    Public relations for Ossur
    Tel: +512 798 7798
    Cell: +310 804 3469
    Email Contact